Market revenue in 2020 | USD 18.8 million |
Market revenue in 2028 | USD 49.6 million |
Growth rate | 12.9% (CAGR from 2020 to 2028) |
Largest segment | Immunological disorders |
Fastest growing segment | Cardiovascular Disorders |
Historical data | 2016 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease |
Key market players worldwide | Quest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.
Immunological disorders was the largest segment with a revenue share of 13.3% in 2020. Horizon Databook has segmented the UK rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.
The UK government has published the UK Strategy for Rare Diseases in 2013, a high-level framework, as a strategic vision for 2013-2020 that covers various key areas including diagnosis & early intervention; empowering patient with rare diseases; identification and prevention of rare diseases; and others.
In February 2019, an update to the implementation plan of this strategy for England was published. Such initiatives by government bodies in the country is one of the key driving forces of this market. In April 2019, Clinithink announced its partnership with Rady Children’s Institute.
For Genomic Medicine (RGIGM) for diagnosis of rare genetic diseases in record time using machine learning process and clinical natural language processing. Such collaborations are expected to expand the use of genome sequencing as a first-line diagnostic test for children with rare genetic disorders.
Horizon Databook provides a detailed overview of country-level data and insights on the UK rare disease genetic testing market , including forecasts for subscribers. This country databook contains high-level insights into UK rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account